We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02032277
First Posted: January 10, 2014
Last Update Posted: October 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
US Oncology Research
NSABP Foundation Inc
Alliance for Clinical Trials in Oncology
German Breast Group
Grupo Español de Investigación del Cáncer de Mama
Information provided by (Responsible Party):
AbbVie
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: November 2, 2020
  Primary Completion Date: March 18, 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: March 2, 2017